Guggenheim raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $25 from $20 and keeps a Buy rating on the shares. The firm, which continues to be “encouraged” by the company’s goal to achieve profitability in early Q3 of 2026, updated its model to reflect Q4 financials.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating
- Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs
- Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)
- Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M
- Phathom Pharmaceuticals Announces $130 Million Public Offering